Aspirin primary prophylaxis: how to identify patients with net benefit

The net benefit of using aspirin for primary prevention of cardiovascular disease (CVD) is quite variable, emphasising the importance of shared decision-making, New Zealand researchers say. An Auckland Univeristy study conducted a benefit-harm analysis on 245,028 adults without established CVD but in whom CVD risk had previously been calculated using the PREDICT web-based decision support ...

Already a member?

Login to keep reading.

© 2021 the limbic